Small Molecule Adjuvants Potentiate Colistin Activity and Attenuate Resistance Development in Escherichia coli by Affecting pmrAB System
Open Access
- 1 July 2020
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 13, 2205-2222
Abstract
Background: Colistin is one of the last-resort antibiotics to treat multi-drug resistant (MDR) Gram-negative bacterial infections in humans. Further, colistin has been also used to prevent and treat Enterobacteriaceae infections in food animals. However, chromosomal mutations and mobile colistin resistance (mcr) genes, which confer resistance to colistin, have been detected in bacterial isolates from food animals and humans worldwide; thus, limiting the use of colistin. Therefore, strategies that could aid in ameliorating colistin resistance are critically needed. Objective: Investigate the adjuvant potential of novel small molecules (SMs) on colistin. Materials and Methods: Previously, we identified 11 membrane-affecting SMs with bactericidal activity against avian pathogenic Escherichia coli (APEC). Here, we investigated the potentiation effect of those SMs on colistin using checkerboard assays and wax moth (Galleria mellonella) larval model. The impact of the SM combination on colistin resistance evolution was also investigated by analyzing whole genome sequences of APEC isolates passaged with colistin alone or in combination with SMs followed by quantitating pmrCAB and pmrH expression in those isolates. Results: The SM combination synergistically reduced the minimum bactericidal concentration of colistin by at least 10-fold. In larvae, the SM combination increased the efficacy of colistin by two-fold with enhanced (> 50%) survival and reduced (> 4 logs) APEC load. Further, the SM combination decreased the frequency (5/6 to 1/6) of colistin resistance evolution and downregulated the pmrCAB and pmrH expression. Previously unknown mutations in pmrB (L14Q, T92P) and pmrA (A80V), which were predicted deleterious, were identified in the colistin-resistant (ColR) APEC isolates when passaged with colistin alone but not in combination with SMs. Our study also identified mutations in hypothetical and several phage-related proteins in ColR APEC isolates in concurrent with pmrAB mutations. Conclusion: Our study identified two SMs (SM2 and SM3) that potentiated the colistin activity and attenuated the development of colistin resistance in APEC. These SMs can be developed as anti-evolution drugs that can slow down colistin resistance development.Keywords
This publication has 62 references indexed in Scilit:
- Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumanniiInternational Journal of Antimicrobial Agents, 2014
- Small Molecule Downregulation of PmrAB Reverses Lipid A Modification and Breaks Colistin ResistanceACS Chemical Biology, 2013
- Antibiotic adjuvants: identification and clinical useMicrobial Biotechnology, 2013
- Colistin: an update on the antibiotic of the 21st centuryExpert Review of Anti-infective Therapy, 2012
- Compound Prioritization Methods Increase Rates of Chemical Probe Discovery in Model OrganismsChemistry & Biology, 2011
- Galleria mellonella as a Model System To Study Acinetobacter baumannii Pathogenesis and TherapeuticsAntimicrobial Agents and Chemotherapy, 2009
- Identification of Minimal Predictors of Avian Pathogenic Escherichia coli Virulence for Use as a Rapid Diagnostic ToolJournal of Clinical Microbiology, 2008
- Quality scores and SNP detection in sequencing-by-synthesis systemsGenome Research, 2008
- Synergy Tests by E Test and Checkerboard Methods of Antimicrobial Combinations against Brucella melitensisJournal of Clinical Microbiology, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001